AI Engines For more Details: Perplexity Kagi Labs You
Chagas Disease Treatment: Nifurtimox is one of the main drugs used in the treatment of Chagas disease, particularly in the acute phase of the infection. Chagas disease is prevalent in parts of Latin America, where it is transmitted to humans primarily through the bite of infected triatomine bugs, also known as "kissing bugs." If left untreated, Chagas disease can lead to chronic complications such as cardiomyopathy (heart disease) and gastrointestinal problems.
Antiprotozoal Activity: Nifurtimox exerts its therapeutic effects by acting as a prodrug that is metabolized to active metabolites within the body. These active metabolites have antiprotozoal properties and work by generating reactive oxygen species (ROS) and free radicals, which are toxic to Trypanosoma cruzi, the parasite responsible for Chagas disease. By targeting the parasite, nifurtimox helps to eliminate the infection from the body and reduce the parasitic burden.
Eradication of Parasites: Nifurtimox is effective in killing both the replicating and non-replicating forms of Trypanosoma cruzi parasites, including the bloodstream trypomastigotes and the intracellular amastigotes. This broad-spectrum activity allows nifurtimox to target the parasite at different stages of its life cycle and disrupt its survival mechanisms, ultimately leading to the clearance of the infection.
Adverse Effects: While nifurtimox is generally effective in treating Chagas disease, it can cause a range of adverse effects, especially during the initial phase of treatment. Common side effects of nifurtimox may include gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea. Other potential side effects may include headache, dizziness, fatigue, anorexia, skin rash, peripheral neuropathy, and psychiatric disturbances.
Monitoring and Management: Patients undergoing treatment with nifurtimox require close monitoring for adverse reactions and may require supportive care to manage symptoms. In some cases, dose adjustments or temporary discontinuation of nifurtimox may be necessary to alleviate side effects. Healthcare providers may also prescribe medications to manage specific symptoms such as nausea or neuropathic pain.
Duration of Treatment: The duration of nifurtimox treatment for Chagas disease may vary depending on factors such as the stage of the infection, the severity of symptoms, and the individual's response to therapy. In general, treatment courses typically last several weeks to months and may involve combination therapy with other antiparasitic medications such as benznidazole.
Effectiveness: Nifurtimox has been shown to be effective in reducing parasitic load and improving clinical outcomes in patients with Chagas disease, particularly when administered during the acute phase of the infection. Early diagnosis and prompt initiation of treatment are crucial for maximizing the effectiveness of nifurtimox therapy and preventing the progression of Chagas disease-related complications.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Escherichia coli | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.9 | 0.9 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 5.1 | 0.6 | 7.5 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 3.4 | 3.1 | 0.1 |
| Allergies | 7.2 | 4.3 | 0.67 |
| Allergy to milk products | 2.2 | 1.6 | 0.38 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 7.5 | 8.3 | -0.11 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 4.3 | 1.1 | 2.91 |
| Ankylosing spondylitis | 5 | 1.8 | 1.78 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.7 | 0.3 | 4.67 |
| Asthma | 5.8 | 3.4 | 0.71 |
| Atherosclerosis | 2.3 | 2.4 | -0.04 |
| Atrial fibrillation | 4.1 | 3.1 | 0.32 |
| Autism | 11.9 | 11.5 | 0.03 |
| Autoimmune Disease | 1.2 | 1 | 0.2 |
| Barrett esophagus cancer | 0.6 | 0.3 | 1 |
| benign prostatic hyperplasia | 0.6 | 0.3 | 1 |
| Biofilm | 2.6 | 2.6 | |
| Bipolar Disorder | 2.4 | 1.7 | 0.41 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Breast Cancer | 0.8 | 0.8 | |
| Cancer (General) | 0.9 | 2.8 | -2.11 |
| Carcinoma | 4.9 | 2.6 | 0.88 |
| Celiac Disease | 3.2 | 4.3 | -0.34 |
| Cerebral Palsy | 1.9 | 1.3 | 0.46 |
| Chronic Fatigue Syndrome | 6.2 | 7.7 | -0.24 |
| Chronic Kidney Disease | 5.2 | 3.4 | 0.53 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.3 | 2 | 0.15 |
| Chronic Urticaria (Hives) | 1.6 | 1.8 | -0.13 |
| Coagulation / Micro clot triggering bacteria | 1.5 | 1.3 | 0.15 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 8.2 | 2.4 | 2.42 |
| Constipation | 2.1 | 0.7 | 2 |
| Coronary artery disease | 2.6 | 3 | -0.15 |
| COVID-19 | 11.7 | 14.5 | -0.24 |
| Crohn's Disease | 10 | 6.9 | 0.45 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 0.8 | 1.9 | -1.37 |
| d-lactic acidosis (one form of brain fog) | 0.2 | 0.2 | |
| deep vein thrombosis | 2.8 | 1.4 | 1 |
| Denture Wearers Oral Shifts | 1.8 | 1.8 | |
| Depression | 13.1 | 11 | 0.19 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 2.3 | 2.2 | 0.05 |
| Endometriosis | 3.1 | 2.2 | 0.41 |
| Eosinophilic Esophagitis | 0.3 | 0.6 | -1 |
| Epilepsy | 4.1 | 2.8 | 0.46 |
| erectile dysfunction | 1.4 | 0.3 | 3.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 6.5 | 4.9 | 0.33 |
| gallstone disease (gsd) | 4 | 1.6 | 1.5 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 2.4 | 1.2 | 1 |
| Generalized anxiety disorder | 3.5 | 2.5 | 0.4 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.6 | 1 | 1.6 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 2.6 | -1.89 |
| Halitosis | 1.8 | 0.3 | 5 |
| Hashimoto's thyroiditis | 4.4 | 2.3 | 0.91 |
| Heart Failure | 5 | 2.4 | 1.08 |
| hemorrhagic stroke | 1.3 | 1.3 | |
| Hidradenitis Suppurativa | 1.4 | 0.3 | 3.67 |
| High Histamine/low DAO | 1.6 | 0.6 | 1.67 |
| hypercholesterolemia (High Cholesterol) | 0.7 | 0.6 | 0.17 |
| hyperglycemia | 2.3 | 2.2 | 0.05 |
| Hyperlipidemia (High Blood Fats) | 1.4 | 0.3 | 3.67 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 5.8 | 6.8 | -0.17 |
| Hypothyroidism | 0.5 | 1 | -1 |
| Hypoxia | 3.7 | 0.3 | 11.33 |
| IgA nephropathy (IgAN) | 1.9 | 5.5 | -1.89 |
| Inflammatory Bowel Disease | 10.2 | 11.7 | -0.15 |
| Insomnia | 2.1 | 3.5 | -0.67 |
| Intelligence | 1.6 | 0.6 | 1.67 |
| Intracranial aneurysms | 1.4 | 0.6 | 1.33 |
| Irritable Bowel Syndrome | 9.6 | 6.4 | 0.5 |
| ischemic stroke | 2.9 | 1.7 | 0.71 |
| Liver Cirrhosis | 8.5 | 5.6 | 0.52 |
| Long COVID | 8.7 | 9.3 | -0.07 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 1.5 | 1.6 | -0.07 |
| Lymphoma | 0.6 | 0.6 | |
| Mast Cell Issues / mastitis | 1.5 | 0.9 | 0.67 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 1 | 1.1 |
| Metabolic Syndrome | 9.1 | 9.6 | -0.05 |
| Mood Disorders | 13.4 | 8.9 | 0.51 |
| multiple chemical sensitivity [MCS] | 1.3 | 0.1 | 12 |
| Multiple Sclerosis | 8.6 | 7 | 0.23 |
| Multiple system atrophy (MSA) | 2.3 | 0.7 | 2.29 |
| myasthenia gravis | 0.9 | 0.7 | 0.29 |
| neuropathic pain | 0.3 | 3.6 | -11 |
| Neuropathy (all types) | 1.2 | 2.2 | -0.83 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.8 | 0.8 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 6.1 | 5.9 | 0.03 |
| NonCeliac Gluten Sensitivity | 1.9 | 0.6 | 2.17 |
| Obesity | 12.5 | 9.7 | 0.29 |
| obsessive-compulsive disorder | 6.6 | 4.8 | 0.38 |
| Osteoarthritis | 3.3 | 1.7 | 0.94 |
| Osteoporosis | 2.5 | 1.9 | 0.32 |
| pancreatic cancer | 1.2 | 0.3 | 3 |
| Parkinson's Disease | 9.9 | 8.3 | 0.19 |
| Polycystic ovary syndrome | 7.9 | 3.7 | 1.14 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.7 | -0.42 |
| Primary sclerosing cholangitis | 3 | 3.2 | -0.07 |
| Psoriasis | 4 | 4 | 0 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 9.6 | 4.7 | 1.04 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 7.8 | 3.6 | 1.17 |
| scoliosis | 0.5 | 1.2 | -1.4 |
| Sjögren syndrome | 3.2 | 3.2 | 0 |
| Sleep Apnea | 2.2 | 1.8 | 0.22 |
| Slow gastric motility / Gastroparesis | 1.1 | 0.3 | 2.67 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.9 | 0.6 | 2.17 |
| Stress / posttraumatic stress disorder | 3.4 | 3.3 | 0.03 |
| Systemic Lupus Erythematosus | 4.9 | 2.4 | 1.04 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 1.4 | 0.3 | 3.67 |
| Type 1 Diabetes | 5.1 | 4.4 | 0.16 |
| Type 2 Diabetes | 10.1 | 8.6 | 0.17 |
| Ulcerative colitis | 6.6 | 8.8 | -0.33 |
| Unhealthy Ageing | 6.8 | 2.9 | 1.34 |
| Vitiligo | 2.5 | 2 | 0.25 |
